Get started
Laurus Labs Ltd.Laurus Labs Ltd.Laurus Labs Ltd.

Laurus Labs Ltd.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsETFs

LAURUSLABS trade ideas

LAURUSLABS Price ActionLaurus Labs Ltd showed strong bullish momentum today, closing near ₹920 and touching an intraday high of ₹921.50. The stock rallied nearly 3% over the previous session, with support coming in at ₹885–890 and sustained buying interest driving it to fresh 52-week and all-time highs. Volumes were robust, and Laurus Labs remains above both its short- and long-term moving averages, reflecting continued upward trend strength. Technical indicators are positive, with the price firmly above the 50- and 200-day averages and momentum readings remaining supportive. Resistance is expected around ₹922–925; a breakout could pave the way for higher targets, while immediate support sits at ₹885 and then ₹860. The stock’s price-to-earnings ratio sits on the higher end, signaling premium valuation thanks to growth expectations and strong fundamentals. In summary, Laurus Labs is in a strong uptrend with bullish technicals and fresh highs, offering positive sentiment unless it drops below key support levels.
NSE:LAURUSLABSLong
by KamalKJoshi
1
Laurus Labs LtdThe Laurus Labs chart displays a clear ascending channel with well-defined upper and lower trend lines, suggesting the stock is in a strong short- to medium-term uptrend. The current price is 923.90, very close to the session high of 926.30, indicating ongoing buying momentum and strength near channel resistance. The price has just broken above the previous consolidation resistance around 900, which now becomes a support zone if the breakout holds. The pattern features higher highs and higher lows, mapped by the parallel channel, with both volume and volatility remaining robust. Given these observations, consider a buying opportunity above 927, with potential targets at 945 and 960.
NSE:LAURUSLABS
by sydrab
LAURUSLABS : Breakout Stock#LAURUSLABS #vcppattern #vcpbreakout #breakoutstock #trendingstock LAURUSLABS : Swing Trade / Short Term >> Rally - Base - now ready for RAlly >> Base = Beautiful Vcp pattern >> VCP pattern Breakout with Volumes >> Trending stock in Momentum >> Good Strength & Volumes Swing Traders can lock profit at 10% and keep Trailing Please Boost, comment and follow us for more Learnings. Disc : Charts shared are for learning purpose only, not a Trade recommendation. Do your own research and consult your financial advisor before taking any position.
NSE:LAURUSLABSLong
by moneyfesttrading
LAURUSLABS - Bullish Trend Intact; Watch for Break Above 9501. Executive Summary Laurus Labs is in a strong bullish momentum phase, trading well above its key Exponential Moving Average (EMA). The stock faces a decisive resistance at 950. A breakout above this level could signal the next leg up, while the trend remains supported on any pullback towards the 856-917 zone. The high RSI suggests caution for immediate entries; prefer buying on dips. 2. Key Technical Observations: Price Action: The stock closed positively at 932.10 (+0.96%), near the day's high of 944, indicating strong buying interest at lower levels. Trend Analysis: The price is trading significantly above the EMA (856.88), confirming a robust medium-term UPTREND. Momentum (RSI): The RSI is at 74.73, indicating the stock is in OVERBOUGHT territory. This suggests the possibility of a short-term consolidation or pullback before the next potential move higher. Key Levels: Resistance: 950 (Immediate & Crucial) Support: 917 (Today's Low) -> 856 (EMA & Strong Trend Support) 3. Trading Plan: Bullish Scenario (Primary Bias): Entry Trigger 1 (Aggressive): A breakout and sustained close above 950 with high volume. Entry Trigger 2 (Conservative): A pullback towards the support zone between 917 - 870 (ideally near the 856 EMA) for a better risk-reward entry. Stop-Loss: Below 850 (A break below the EMA would invalidate the bullish structure). Target 1: 1000 Target 2: 1025 - 1050 Bearish Scenario (Caution Signal): A break below the 856 EMA support could lead to a deeper correction towards 800. This is not the primary expectation but a key level to watch for risk management.
NSE:LAURUSLABSLong
by kingofstockmarkets
Laurus Labs Ltd. (LAURUSLABS)Hello Traders ! Laurus Labs has shown strong performance in recent periods, often outperforming its sector and broader market indices like the Sensex and Nifty Pharma. Here's a concise overview based on available data: This is Laurus Lab weekly chart. just see from October 2024 no matter how long the Up trend stay but down trend stay every three weeks. This is 1st week. Hopefully we are enjoy bear move 2 weeks more,have a good day , stay tuned .
NSE:LAURUSLABSShort
by askbiswanath2025
Rounding Bottom Breakout > Laurus LabsLAURUS LABS Trade details mentioned in the Chart Gist : LTP 822 Buy Dips 760 SL CLB 695 Tgt upto 1150 📌 Stick to levels. Follow discipline. Let the trade work for you. 📌Please Follow TSL (Trailing Stop Loss) To help maximize your profits and protect gains as the trade progresses. Let’s stay hopeful that the move continues as per our expectations! 📈 💡 Liked the idea? Then don’t forget to Boost 🚀 it! For more insights & trade ideas, 📲 Visit my profile and hit Follow Warm regards, Naresh G SEBI Registered Research Analyst
NSE:LAURUSLABSLong
by NareshG_SEBI_REGISTERED_RA
1
LAURUSLABS - Due for a pullback? a nice TRADING Set up with LRHRTF: 15 minutes and 75 minutes On 15 minutes TF, the price seems to have completed a 5 wave impulse from 641. Since the iii rd wave was extended, I have projected the v th wave to be at wave 1 = wave 5; and is placed at 798 Price has been consolidating at this zone for about 3 days and hasn't been able to break and close above so far. if it breaks and trades above 800, then there is a fair chance that the price can test 820-830 levels.. In either case, this is not a place to go long.. Better to wait for pullback.. On 75 minutes TF, price seems to have completed 3rd wave.. The possible counts and alt counts with internal counts (two different case scenarios placed) are copied below.. Primary view: Alt view: As you can see, price has been witnessing a strong/non-stop impulse from 640 and the exhaustion is seen recently. Pullback towards 720 could offer some buying opportunity.. but for now, from 790-800 to 720, this looks like a very good trading set up to try with. A break below 780 (1st confirmation) and 760 are the levels to watched. Previous ATH at 723.75 and FVG is at 700 38-50% fib retracement are at 740 and 720 respectively Disclaimer: I am not a SEBI registered Analyst and this is not a trading advise. Views are personal and for educational purpose only. Please consult your Financial Advisor for any investment decisions. Please consider my views only to get a different perspective (FOR or AGAINST your views). Please don't trade FNO based on my views. If you like my analysis and learnt something from it, please give a BOOST. Feel free to express your thoughts and questions in the comments section.
NSE:LAURUSLABS
by Murthy_Santhosh
Laurus Labs Limited (LAURUSLABS)Laurus Labs Limited, an Indian pharmaceutical and biotechnology company headquartered in Hyderabad, operates a diversified and integrated business model focused on innovation, affordability, and global reach in the pharmaceutical industry. Founded in 2005 by Dr. Satyanarayana Chava, the company leverages its expertise in research, development, and manufacturing to serve global pharmaceutical markets. Core Business Segments Laurus Labs operates through three primary business segments, each contributing to its revenue and growth strategy: Laurus Generics: Active Pharmaceutical Ingredients (APIs): Laurus Labs is a global leader in manufacturing high-quality APIs, particularly for anti-retroviral (ARV), oncology, cardiovascular, anti-diabetic, anti-asthma, gastroenterology, and hepatitis C therapeutics. It holds one of the largest high-potent API manufacturing capacities in India and is a leading third-party supplier of ARV APIs globally, serving nine of the top ten generic pharmaceutical companies. This segment accounted for 46% of revenue in the first nine months of FY25, up from 41% in FY22. Finished Dosage Forms (FDFs): The company produces oral solid formulations, including tablets for ARVs, anti-diabetics, cardiovascular, and proton pump inhibitors (PPIs). Its state-of-the-art FDF facility has a capacity of 1 billion tablets per year, expandable to 5 billion, enabling it to cater to both generic and proprietary markets. Laurus Synthesis: This segment focuses on contract development and manufacturing organization (CDMO) services, providing key starting materials (KSM), intermediates, and APIs for new chemical entities (NCEs). Laurus Synthesis serves global innovators from clinical phase drug development to commercial manufacturing, with key markets in the US, EU, and Japan. The company’s strong process chemistry skills and fungible manufacturing facilities allow flexibility to meet client demands, contributing to its reputation as a trusted CDMO partner. Recent expansions, such as the new API and CDMO manufacturing unit at APSEZ, Visakhapatnam, aim to strengthen its global CDMO presence. The CDMO business is described as "lumpy" due to project-based timelines but is a high-growth area, with the company managing multiple projects and leveraging technological advancements to attract clients. Laurus Bio: Laurus Labs entered the biotechnology sector through the acquisition of Richcore Lifesciences (renamed Laurus Bio Pvt Ltd) in 2020. This segment focuses on recombinant products, animal-origin-free proteins, and enzymes for biopharma, nutraceuticals, dietary supplements, alternate food proteins, and cosmeceuticals. Laurus Bio develops novel enzymatic solutions and provides CDMO services for biologics, with facilities near Bengaluru. Investments, such as the INR 39.99 crore infusion in FY25, indicate a strategic focus on scaling up biotech capabilities. Key Components of the Business Model Research and Development (R&D): Laurus Labs is a science-led company with state-of-the-art R&D centers in Hyderabad, Visakhapatnam, and the US. It employs over 1,050 scientists and has filed 322 patents, owning 184, reflecting a strong focus on innovation. R&D efforts target high-growth areas like ARVs, oncology, and biotechnology, enabling the development of new cures and cost-effective solutions. Services include drug substance development, drug product development, biologics development, and analytical research, supporting both in-house products and CDMO clients. Global Manufacturing and Regulatory Compliance: The company operates eight manufacturing plants in Visakhapatnam, Hyderabad, and Bangalore, with approvals from global regulatory bodies such as USFDA, WHO, PMDA (Japan), MHRA (UK), TGA, and BfArM (Germany). These facilities support large-scale commercial API production and FDF manufacturing, ensuring high-quality and affordable medicines. Recent USFDA audits, such as the successful inspection of its Hyderabad API facility, highlight its compliance standards. Laurus Labs has expanded its manufacturing footprint, with new units like Unit 4 and a second Laurus Bio plant near Bengaluru, to support growing demand. Global Market Reach: Laurus Labs sells APIs in 56 countries and works with all top 10 generic pharmaceutical companies globally. Its subsidiaries in the US, UK, Germany, and South Africa (Laurus Generics SA) enhance its market presence and service capabilities. The company’s focus on exports generates significant revenue from markets like the US, EU, and Japan. Strategic Acquisitions and Investments: Laurus Labs has pursued strategic acquisitions to diversify its portfolio, such as acquiring a 72.55% stake in Richcore Lifesciences (Laurus Bio) for INR 246.7 crore in 2020 and a 33.86% stake in ImmunoACT, a CAR-T cell therapy company, for INR 80 crore in 2023. These moves strengthen its biotechnology and cell/gene therapy capabilities. Investments in subsidiaries like Laurus Synthesis Pvt. Ltd. and Laurus Generics Inc. support its CDMO and generics businesses. Sustainability and ESG Focus: Laurus Labs integrates environmental, social, and governance (ESG) principles into its operations, emphasizing sustainable soil and water management, community welfare, and transparency. Initiatives like the Laurus Charitable Trust and partnerships with organizations like ICRISAT reflect its commitment to social responsibility. Revenue and Growth Strategy Revenue Composition: In Q1 FY25, Laurus Labs reported revenues of INR 1,195 crore, with the generics segment (APIs and FDFs) being the largest contributor, followed by CDMO and biotech. The company has shifted from heavy reliance on ARV APIs (down from 70% to 10-15% of revenue in recent years) to a more diversified portfolio, with CDMO and biotech expected to drive future growth. Growth Drivers: The company focuses on high-growth areas like oncology, biotechnology, and CDMO services. Its fungible facilities allow flexibility to adapt to client needs, and investments in capacity expansion (e.g., new CDMO units and biotech facilities) position it for scalability. Challenges: The ARV API segment faces limited growth due to declining new HIV infections, and the CDMO business is subject to project-based volatility. External factors, such as potential US tariffs on pharmaceuticals, have impacted stock performance. Competitive Positioning Laurus Labs differentiates itself through cost-effective manufacturing, strong R&D, and regulatory compliance, making it a preferred partner for global pharmaceutical companies. Its ability to serve both generic and proprietary markets, combined with its biotechnology expansion, positions it as a leader in the CRAMS (Contract Research and Manufacturing Services) space. The company’s peers include Sun Pharmaceutical, Divi’s Laboratories, Cipla, Dr. Reddy’s, and Biocon, but Laurus stands out for its integrated API-to-FDF capabilities and growing CDMO and biotech presence.
BSE:LAURUSLABS
by askbiswanath2025
1
Laurus Labs – Primed for a Multi-Year Breakout?Technical Analysis ✅ 1. Price Structure: Higher Highs, Higher Lows The chart shows strong base-building over nearly 2 years following the explosive rally in 2020. Price formed a consolidation zone between ₹430–₹640, absorbing previous supply. Recent candles show tight price action and multiple Break of Structure (BOS) events — a classic signature of institutional accumulation. It is now approaching the all-time high zone (~₹720), acting as a key breakout level. 📊 2. Multi-Year Base Breakout Setup The current price action forms an ascending base, which often precedes explosive continuation in trending stocks. The price has moved up in tight bands with shallow corrections, reflecting volatility contraction — another bullish pattern. If price decisively breaks above ₹720 with volume, it could trigger a long-term uptrend continuation. 📈 3. Relative Strength (RS) vs Nifty The RS line has finally turned positive after a prolonged underperformance (2022–2023). Sustained RS strength on a weekly chart signals potential leadership behavior. The stock is now outperforming the benchmark, which is a critical filter in breakout selection. 📉 4. Moving Averages: Strong Alignment All major EMAs (20, 50, 100, 200 weekly) are now curved upward, showing a healthy trending environment. Price is comfortably trading above all EMAs, acting as dynamic support and confirming trend strength. 50-week EMA recently crossed above the 200-week EMA — a bullish long-term signal (Golden Cross on weekly). 🔊 5. Volume Analysis Volume is slightly muted but stable and consistent, indicating quiet accumulation. A breakout candle with a volume surge above the historical average would be ideal confirmation. The lack of wide-range down bars suggests distribution is absent. 🧠 Summary and Trade Plan ▶️ Bullish Case: Break and close above ₹720 on strong volume can activate a long-term trend continuation. Potential for a measured move of ~₹200–₹250, taking the stock toward ₹900–₹950 over time, if momentum sustains. ⛔ Bearish Risk: A rejection from ₹720 without follow-through, especially with increasing volume, may result in range re-entry. Invalidated if stock closes below ₹630–640 on the weekly chart. 🎯 Entry Watch: Ideal entry: Breakout + retest of ₹720 with narrowing candles. Aggressive entry: Around CMP with stop-loss below ₹630 and trail the stop as it trends. 🧭 Final Thoughts Laurus Labs is showing a mature base with breakout-ready structure. The trend strength, relative performance, and BOS stack-up make it one of the cleaner charts among mid-cap pharma names. All eyes should be on price action and volume near the ₹720 zone — this is where smart money often tips its hand.
NSE:LAURUSLABSLong
by Sudhi4488
1
Laurus Labs Limited - Breakout Setup, Move is ON...#LAURUSLABS trading above Resistance of 553 Next Resistance is at 699 Support is at 420 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:LAURUSLABSLong
by MandeepSinghKohli
LAURUS LABS LTD ANALYSISFOR LEARNING PURPOSE LAURUS LABS LTD - The current price of LAURUS LABS LTD is 666.60 rupees I am going to buy this stock because of the reasons as follows- 1. Its coming out from a good consolidation base 2. It broke a strong resistance zone and making 4 year high 3. It is showing better relative strength as it stood strong in volatile times 4. The risk and reward is favourable 5. The stock is famous and it belongs to a sector which is defensive and has not done much in last weeks so I am expecting some move from that. 6. The stock was very strong in 2020-2021 and it needed a good rest which it got in last 4 years 7. The stock has been outperforming major Index as well as Sectoral Index which is a good sign I will buy it with minimum target of 35-40% and then will trail after that. My SL is at 588 rupees I will be managing my risk.
NSE:LAURUSLABSLong
by Its_Bhushan
2
LAURUSLABS | Cup and Handle | Weekly | Breakout ### 📈 **Weekly Chart Overview:** ✅ **Cup and Handle breakout pattern** * **Cup base:** ₹278.85 * **Resistance breakout:** ₹644.85 * **Current price:** ₹676.45 (+5.36% move) * **Measured move target:** ₹1,003.50 (approx. 56–57% projected upside). --- ### 📊 **Key Chart Signals:** * **Cup and Handle formation:** Clear bottom rounding out and handle consolidation breakout above ₹644.85. * **Volume spike** near breakout confirms buying strength. * **RSI:** Just breaking out of a long-term descending trendline, hinting at fresh momentum. --- ### 🔍 **Next Key Levels:** * **Immediate resistance:** ₹700 zone (weekly highs) * **Measured move target:** ₹1,003–1,005 * **Support zone:** ₹644–645 (handle breakout level). --- ### 💡 **Key Takeaway:** The **weekly Cup and Handle breakout** suggests **strong long-term momentum** for Laurus Labs, with a projected target near ₹1,000. It’s important to watch for **confirmation above ₹700**, which would further support the bullish move.
NSE:LAURUSLABSLong
by DailyCharts03